|
US7744877B2
(en)
*
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6306393B1
(en)
*
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
WO2001060397A1
(en)
*
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
|
PT1974747E
(pt)
|
1998-08-11 |
2012-09-05 |
Biogen Idec Inc |
Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
|
|
HK1041811A1
(zh)
*
|
1998-11-09 |
2002-07-26 |
Idec药物公司 |
接受bmt或pbsc移植患者的抗cd20嵌合抗体治疗
|
|
ES2543819T3
(es)
|
1998-11-09 |
2015-08-24 |
Biogen Inc. |
Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
|
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
|
WO2000063719A1
(en)
*
|
1999-04-20 |
2000-10-26 |
Synthes Ag Chur |
Device for the percutaneous obtainment of 3d-coordinates on the surface of a human or animal organ
|
|
WO2000067796A1
(en)
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
US7527787B2
(en)
*
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
US7550143B2
(en)
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
|
US7312318B2
(en)
*
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
DE60042785D1
(de)
*
|
1999-06-09 |
2009-10-01 |
Immunomedics Inc |
Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
|
|
KR20020027490A
(ko)
*
|
1999-07-12 |
2002-04-13 |
제넨테크, 인크. |
Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
|
|
US6451284B1
(en)
*
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
|
US20020006404A1
(en)
*
|
1999-11-08 |
2002-01-17 |
Idec Pharmaceuticals Corporation |
Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
WO2001055336A2
(en)
*
|
2000-01-25 |
2001-08-02 |
Hyseq, Inc. |
Methods and materials relating to cd84-like polypeptides and polynucleotides
|
|
WO2001074388A1
(en)
*
|
2000-03-31 |
2001-10-11 |
Idec Pharmaceuticals Corporation |
Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
|
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
|
|
EP1296714B1
(en)
*
|
2000-06-22 |
2009-08-26 |
University Of Iowa Research Foundation |
Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
|
|
JP2004508420A
(ja)
*
|
2000-09-18 |
2004-03-18 |
アイデック ファーマスーティカルズ コーポレイション |
Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
|
|
US8034903B2
(en)
|
2000-10-20 |
2011-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Degraded TPO agonist antibody
|
|
AU2002213357A1
(en)
*
|
2000-10-20 |
2002-05-06 |
Idec Pharmaceuticals Corporation |
Variant igg3 rituxan r and therapeutic use thereof
|
|
US7592005B2
(en)
*
|
2000-12-28 |
2009-09-22 |
Kirin Beer Kabushiki Kaisha |
Monoclonal antibody
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
JP4384852B2
(ja)
*
|
2001-01-17 |
2009-12-16 |
イントリート ピーティーワイ リミテッド |
非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
|
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
NZ527283A
(en)
*
|
2001-01-29 |
2006-03-31 |
Biogen Idec Inc |
Modified antibodies and methods of use
|
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
AU2002311919B8
(en)
|
2001-05-11 |
2007-03-22 |
Ludwig Institute For Cancer Research Ltd |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
JP2004529945A
(ja)
*
|
2001-05-17 |
2004-09-30 |
ラ ホヤ ファーマシューティカル カンパニー |
Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
|
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
BR0211614A
(pt)
*
|
2001-08-03 |
2006-10-31 |
Genentech Inc |
polipeptìdeo tacis e br3 e empregos dos mesmos
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
US7355012B2
(en)
|
2001-09-26 |
2008-04-08 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
|
|
CA2476555A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Nuvelo, Inc. |
Methods of therapy and diagnosis
|
|
WO2003072736A2
(en)
|
2002-02-21 |
2003-09-04 |
Duke University |
Reagents and treatment methods for autoimmune diseases
|
|
US8491896B2
(en)
*
|
2002-06-14 |
2013-07-23 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US8435529B2
(en)
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
|
US6991653B2
(en)
*
|
2002-03-21 |
2006-01-31 |
Sdgi Holdings, Inc. |
Vertebral body and disc space replacement devices
|
|
EP1500400A4
(en)
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT WITH ANTIBODY COMPOSITION
|
|
EP1622645B1
(en)
*
|
2002-04-23 |
2013-10-23 |
Roger Williams Hospital |
Compositions and methods for stem cell delivery
|
|
SG187991A1
(en)
|
2002-05-02 |
2013-03-28 |
Wyeth Corp |
Calicheamicin derivative-carrier conjugates
|
|
EP1507562B1
(en)
*
|
2002-05-29 |
2010-03-24 |
Immunomedics, Inc. |
Compositions for radioimmunotherapy of brain
|
|
US9599619B2
(en)
|
2002-06-14 |
2017-03-21 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
|
ES2524767T3
(es)
*
|
2002-06-14 |
2014-12-12 |
Immunomedics, Inc. |
Anticuerpo monoclonal humanizado HPAM4
|
|
RU2005100777A
(ru)
*
|
2002-06-14 |
2005-08-27 |
Иммуномедикс, Инк. (Us) |
Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы
|
|
US8821868B2
(en)
|
2002-06-14 |
2014-09-02 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
WO2004011611A2
(en)
*
|
2002-07-25 |
2004-02-05 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
US20090217404A1
(en)
*
|
2002-09-27 |
2009-08-27 |
Lowe Scott W |
Cell-based RNA interference and related methods and compositions
|
|
AU2003271175A1
(en)
|
2002-10-11 |
2004-05-04 |
Masahiro Abe |
Cell death-inducing agent
|
|
BRPI0315295C1
(pt)
*
|
2002-10-17 |
2021-05-25 |
Genmab As |
anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
|
US20040120949A1
(en)
*
|
2002-11-08 |
2004-06-24 |
Boehringer Ingelheim International Gmbh |
Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
|
|
DE60332483D1
(de)
|
2002-11-15 |
2010-06-17 |
Novartis Vaccines & Diagnostic |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
|
NZ561600A
(en)
|
2002-11-19 |
2009-04-30 |
Clluone Therapeutics As |
Methods and kits for diagnosing and treating B-cell chronic lymphocytic leukemia (B-CLL)
|
|
US8420086B2
(en)
*
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
TWI335821B
(en)
*
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
WO2004074445A2
(en)
*
|
2003-02-17 |
2004-09-02 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in tumor resistance to chemotherapy
|
|
US20090186839A1
(en)
*
|
2003-02-17 |
2009-07-23 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in chemoresistance
|
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
|
EP1609803A4
(en)
*
|
2003-03-31 |
2006-05-24 |
Chugai Pharmaceutical Co Ltd |
MODIFIED ANTIBODY AGAINST CD22 AND APPLICATIONS THEREOF
|
|
EP1613350B1
(en)
*
|
2003-04-09 |
2009-03-18 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
|
CN1802388B
(zh)
*
|
2003-05-09 |
2011-01-05 |
杜克大学 |
Cd20特异抗体及使用它们的方法
|
|
CN1816356A
(zh)
*
|
2003-05-14 |
2006-08-09 |
免疫原公司 |
药物缀合物组合物
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
JP2007526220A
(ja)
|
2003-06-05 |
2007-09-13 |
ジェネンテック・インコーポレーテッド |
Ｂ細胞疾患の併用療法
|
|
US9005613B2
(en)
|
2003-06-16 |
2015-04-14 |
Immunomedics, Inc. |
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
|
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
|
US20050032130A1
(en)
*
|
2003-07-29 |
2005-02-10 |
Genentech, Inc. |
Neutralizing antibody assay and uses therefor
|
|
CA2534639C
(en)
|
2003-07-31 |
2013-07-30 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
WO2005014618A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
MXPA06002134A
(es)
*
|
2003-08-29 |
2006-05-31 |
Genentech Inc |
Terapia de trastornos oculares.
|
|
MXPA06004035A
(es)
|
2003-10-16 |
2006-08-31 |
Micromet Ag |
Aglutinantes cd3 de-inmunizados multi-especificos.
|
|
CN1878568A
(zh)
*
|
2003-11-05 |
2006-12-13 |
盘林京有限公司 |
Cdim结合抗体的增强的b细胞细胞毒性
|
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
|
JPWO2005053741A1
(ja)
*
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
|
|
KR20060107555A
(ko)
*
|
2003-12-19 |
2006-10-13 |
제넨테크, 인크. |
이식 거부에서 ｃｄ20의 검출
|
|
CN1917901A
(zh)
*
|
2003-12-19 |
2007-02-21 |
健泰科生物技术公司 |
自身免疫病疗法中cd20的检测
|
|
SI2311873T1
(sl)
|
2004-01-07 |
2018-12-31 |
Novartis Vaccines And Diagnostics, Inc. |
M-CSF-specifična monoklonska protitelesa in njihova uporaba
|
|
US20080299546A1
(en)
*
|
2004-02-10 |
2008-12-04 |
Nihon University |
Canine Cd20 Gene
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US8034352B2
(en)
*
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8003111B2
(en)
*
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
AU2005247303A1
(en)
*
|
2004-04-16 |
2005-12-08 |
Genentech, Inc. |
Treatment of polychondritis and mononeuritis multiplex with anti-CD20 antibodies
|
|
CA2563432A1
(en)
*
|
2004-04-16 |
2005-12-01 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
|
US7850962B2
(en)
*
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
|
ZA200608982B
(en)
*
|
2004-05-05 |
2008-06-25 |
Genentech Inc |
Preventing autoimmune disease by using an anti-CD20 antibody
|
|
US9228008B2
(en)
*
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
|
US7531628B2
(en)
*
|
2004-05-28 |
2009-05-12 |
Idexx Laboratories, Inc. |
Canine CD20 compositions
|
|
AU2005249566B2
(en)
*
|
2004-06-04 |
2010-11-11 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
|
MXPA06014067A
(es)
*
|
2004-06-04 |
2007-02-15 |
Genentech Inc |
Metodo para tratar lupus.
|
|
BRPI0513100A
(pt)
*
|
2004-07-22 |
2007-10-23 |
Genentech Inc |
métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
|
|
AU2005274905B2
(en)
|
2004-08-04 |
2010-12-23 |
Mentrik Biotech, Llc |
Variant Fc regions
|
|
AU2005334481A1
(en)
*
|
2004-08-11 |
2007-01-25 |
Trubion Pharmaceuticals, Inc. |
Binding domain fusion proteins
|
|
TW200621282A
(en)
*
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
|
BRPI0516297A
(pt)
*
|
2004-10-05 |
2008-09-02 |
Genentech Inc |
métodos de tratamento de vasculite e artigos de fabricação
|
|
AU2005313971B2
(en)
*
|
2004-12-08 |
2011-10-13 |
Immunomedics, Inc. |
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
|
|
US8137907B2
(en)
*
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
|
US10206998B2
(en)
|
2005-01-12 |
2019-02-19 |
Proteonova, Inc. |
Modular targeted therapeutic agents and methods of making same
|
|
US20080199499A1
(en)
*
|
2005-01-12 |
2008-08-21 |
Proteonova, Inc. |
Method for Making Targeted Therapeutic Agents
|
|
TW200637574A
(en)
*
|
2005-01-13 |
2006-11-01 |
Genentech Inc |
Treatment method
|
|
MX2007008781A
(es)
*
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
|
CN101146532B
(zh)
*
|
2005-01-21 |
2012-05-09 |
阿斯泰克斯治疗有限公司 |
药物化合物
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
EP1845975A1
(en)
*
|
2005-01-21 |
2007-10-24 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors and further antitumor agents
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
HUE025945T2
(en)
|
2005-02-15 |
2016-07-28 |
Univ Duke |
Anti-CD19 antibodies and their applications in oncology
|
|
US8444973B2
(en)
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
ES2665422T3
(es)
|
2005-03-03 |
2018-04-25 |
Immunomedics Inc. |
Anticuerpos L243 humanizados
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
CA2604032C
(en)
*
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
|
ZA200708857B
(en)
*
|
2005-04-22 |
2009-01-28 |
Genentech Inc |
Method for treating dementia or alzheimer's disease with a CD30 antibody
|
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
EP1885755A4
(en)
*
|
2005-05-05 |
2009-07-29 |
Univ Duke |
CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
|
|
ZA200709956B
(en)
*
|
2005-05-20 |
2009-02-25 |
Genentech Inc |
Pretreatment of a biological sample from an autoimmune disease subject
|
|
CA2610265A1
(en)
*
|
2005-05-31 |
2007-05-10 |
Cold Spring Harbor Laboratory |
Methods for producing micrornas
|
|
JP2008546647A
(ja)
*
|
2005-06-08 |
2008-12-25 |
デューク ユニバーシティ |
移植のための抗−ｃｄ１９抗体治療
|
|
CA2611726C
(en)
|
2005-06-10 |
2017-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(fv)2
|
|
CA2611814A1
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
|
RU2421242C2
(ru)
|
2005-07-25 |
2011-06-20 |
Трабьон Фармасьютикалз, Инк. |
Применение однократной дозы cd20-специфических связывающих молекул
|
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
RU2423381C2
(ru)
*
|
2005-07-25 |
2011-07-10 |
Трабьон Фармасьютикалз, Инк. |
Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
|
|
EP2277916A3
(en)
*
|
2005-07-28 |
2011-04-27 |
Novartis AG |
Use of antibody to M-CSF
|
|
JP5457671B2
(ja)
*
|
2005-07-28 |
2014-04-02 |
ノバルティス アーゲー |
Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
|
|
WO2007019232A2
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
US8883162B2
(en)
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20090155850A1
(en)
*
|
2005-10-28 |
2009-06-18 |
The Florida International University Board Of Trustees |
Horse:Human Chimeric Antibodies
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
ES2618543T3
(es)
*
|
2005-11-23 |
2017-06-21 |
Genentech, Inc. |
Métodos y composiciones relacionados con ensayos de linfocitos B
|
|
GB0525214D0
(en)
|
2005-12-12 |
2006-01-18 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
EP2674440B1
(en)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
JP2009532336A
(ja)
*
|
2006-03-06 |
2009-09-10 |
メディミューン，エルエルシー |
ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
|
|
EP1999148B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
CA2651178A1
(en)
*
|
2006-05-03 |
2007-11-05 |
Sydney Welt |
Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
|
|
US20090318500A1
(en)
*
|
2006-05-05 |
2009-12-24 |
Astex Therapeutics Limited |
4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer
|
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
|
CA2659820A1
(en)
*
|
2006-08-04 |
2008-02-14 |
Novartis Ag |
Ephb3-specific antibody and uses thereof
|
|
AR064801A1
(es)
|
2006-08-18 |
2009-04-29 |
Xoma Technology Ltd |
Anticuerpo especifico prlr (receptor de prolactina) y sus usos
|
|
RU2495882C2
(ru)
*
|
2006-09-08 |
2013-10-20 |
Медиммун, Ллк. |
Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
|
|
JP2010505426A
(ja)
*
|
2006-10-10 |
2010-02-25 |
バイオスセプター インターナショナル リミテッド |
非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
|
|
WO2008043146A1
(en)
*
|
2006-10-10 |
2008-04-17 |
Biosceptre International Limited |
Antibodies against non functional p2x7 receptor
|
|
US8481683B2
(en)
|
2006-12-01 |
2013-07-09 |
Medarex, Inc. |
Human antibodies that bind CD22 and uses thereof
|
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
|
AU2007343610C1
(en)
*
|
2007-01-17 |
2013-11-07 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
TW201307390A
(zh)
|
2007-02-02 |
2013-02-16 |
Amgen Inc |
海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
|
|
EP2118344B1
(en)
|
2007-02-12 |
2014-07-23 |
Proteonova, Inc. |
GENERATION OF LIBRARY OF SOLUBLE RANDOM POLYPEPTIDES LINKED TO mRNA
|
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US7906117B2
(en)
*
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
|
KR20170036814A
(ko)
*
|
2007-05-21 |
2017-04-03 |
앨더바이오 홀딩스 엘엘씨 |
신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
|
|
DK2164514T3
(en)
|
2007-05-21 |
2017-02-27 |
Alderbio Holdings Llc |
Antibodies to IL-6 and its use
|
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
KR102055873B1
(ko)
|
2007-07-09 |
2019-12-13 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
|
CN108424454B
(zh)
*
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
|
ATE542139T1
(de)
|
2007-09-14 |
2012-02-15 |
Biosceptre Int Ltd |
Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
|
|
ES2619681T3
(es)
|
2007-09-14 |
2017-06-26 |
Biosceptre (Aust) Pty Ltd |
Novedosos epítopos P2X7
|
|
HUE030134T2
(en)
|
2007-10-16 |
2017-04-28 |
Zymogenetics Inc |
Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
|
|
DK2211904T3
(en)
|
2007-10-19 |
2016-10-24 |
Seattle Genetics Inc |
Cd19-binding agents and uses thereof
|
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
WO2009094551A1
(en)
|
2008-01-25 |
2009-07-30 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
|
WO2009124109A1
(en)
|
2008-04-04 |
2009-10-08 |
The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services |
Human monoclonal antibodies specific for cd22
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
RU2531754C2
(ru)
*
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
US9315577B2
(en)
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
|
CN102143978B
(zh)
|
2008-07-04 |
2015-02-18 |
生物权威国际有限公司 |
抗p2x7肽和表位
|
|
AU2011207189B2
(en)
|
2008-08-08 |
2014-01-16 |
Immunomedics, Inc. |
Detection of early-stage pancreatic adenocarcinoma
|
|
CN102186499B
(zh)
*
|
2008-08-20 |
2015-05-20 |
Ibc医药公司 |
用于癌症治疗的对接和锁定(dnl)疫苗
|
|
EP2331579B1
(en)
*
|
2008-09-04 |
2017-07-05 |
Vet Therapeutics, Inc. |
Monoclonal antibodies
|
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
|
WO2010051215A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Proteonova, Inc. |
Methods for making hiv vaccines and related compositions
|
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US9452227B2
(en)
*
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
WO2010093450A2
(en)
|
2009-02-11 |
2010-08-19 |
Ludwing Institute For Cancer Research Ltd. |
Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
|
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
ES3000111T3
(en)
|
2009-02-13 |
2025-02-27 |
Immunomedics Inc |
Intermediates for preparing conjugates with an intracellularly-cleavable linkage
|
|
EP2411050A4
(en)
*
|
2009-03-25 |
2013-07-17 |
Vet Therapeutics Inc |
ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
|
|
WO2011006510A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Technical University Of Denmark |
Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
|
|
HRP20200768T4
(hr)
|
2009-08-11 |
2025-03-28 |
F. Hoffmann - La Roche Ag |
Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
|
|
EP2467404B1
(en)
|
2009-08-20 |
2015-09-30 |
Biosceptre International Limited |
Anti p2x7 receptor antibodies and fragments thereof
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
EP2480888B1
(en)
|
2009-09-25 |
2016-11-30 |
XOMA Technology Ltd. |
Screening methods
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
WO2011040973A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
|
|
CA2776037A1
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
|
CN102740888B
(zh)
|
2009-11-24 |
2016-10-12 |
奥尔德生物制药公司 |
Il-6抗体及其用途
|
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
WO2011075789A1
(en)
|
2009-12-24 |
2011-06-30 |
Biosceptre International Limited |
Antibodies to non-functional oligomeric p2x7 receptors
|
|
EP2523680A4
(en)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
REINFORCED CYTOTOXICITY OF ANTIBODIES TO CD74 AND HLA-DR WITH INTERFERON GAMMA
|
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Ｃｄ２０ 항체 및 이의 용도
|
|
EP2542258A4
(en)
*
|
2010-03-04 |
2013-08-21 |
Vet Therapeutics Inc |
ON CD52 MONOCLONAL ANTIBODIES
|
|
US9616120B2
(en)
*
|
2010-03-04 |
2017-04-11 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD20
|
|
EP2576622A4
(en)
|
2010-06-01 |
2013-11-27 |
Univ Monash |
ON THE UNPROCESSED RECEPTOR TYROSINE KINASE C-MET TARGETED ANTIBODIES
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2613808B1
(en)
|
2010-09-10 |
2017-11-08 |
Biosceptre (Aust) Pty Ltd |
Companion animal cancer treatments with an anti p2x7 antibody
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
CA2815046C
(en)
|
2010-10-19 |
2019-05-14 |
Mayo Foundation For Medical Education And Research |
Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
|
|
WO2012057765A1
(en)
|
2010-10-28 |
2012-05-03 |
The Board Of Regents Of The University Of Texas System |
Recombinant anti-cd19 monoclonal antibodies
|
|
CA2818813C
(en)
|
2010-11-23 |
2020-10-06 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of oral mucositis
|
|
JP5947807B2
(ja)
*
|
2010-12-14 |
2016-07-06 |
テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ |
ナノ粒子組成物への放射性核種の封入
|
|
EP2675485A4
(en)
|
2011-02-15 |
2014-10-15 |
Immunomedics Inc |
ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
CN103732623B
(zh)
|
2011-06-03 |
2017-09-29 |
佐马技术有限公司 |
对TGF‑β具有特异性的抗体
|
|
MX349321B
(es)
|
2011-07-01 |
2017-07-21 |
Biosceptre (Aust) Pty Ltd |
Terapia combinada.
|
|
WO2013012894A1
(en)
|
2011-07-18 |
2013-01-24 |
The Ohio State University |
Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
GB2495113A
(en)
*
|
2011-09-29 |
2013-04-03 |
Bioinvent Int Ab |
Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
AU2012328819B2
(en)
|
2011-10-26 |
2017-08-03 |
Elanco Tiergesundheit Ag |
Monoclonal antibodies and methods of use
|
|
WO2013085893A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
CN108285483B
(zh)
|
2012-04-17 |
2022-04-26 |
梅奥医学教育和研究基金会 |
用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
CN104619350A
(zh)
|
2012-06-14 |
2015-05-13 |
Ambrx公司 |
结合到核受体配体多肽的抗psma抗体
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
CN104379169A
(zh)
|
2012-08-14 |
2015-02-25 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
US20240139324A1
(en)
|
2012-12-13 |
2024-05-02 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
JP2016513098A
(ja)
|
2013-02-07 |
2016-05-12 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
|
|
EP3666795A1
(en)
|
2013-03-12 |
2020-06-17 |
Molecular Templates, Inc. |
Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
|
|
WO2014159242A1
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Notch 3 mutants and uses thereof
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US9452228B2
(en)
|
2013-04-01 |
2016-09-27 |
Immunomedics, Inc. |
Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
ES2881306T3
(es)
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
US9416197B2
(en)
|
2013-11-01 |
2016-08-16 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
|
|
CN112851769A
(zh)
|
2014-01-27 |
2021-05-28 |
分子模板公司 |
用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
|
CN106604934A
(zh)
|
2014-06-11 |
2017-04-26 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
|
EP3160504B1
(en)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
WO2016073963A1
(en)
|
2014-11-07 |
2016-05-12 |
Mayo Foundation For Medical Education And Research |
Treatment of neonatal hypoxia including impairments or effects thereof
|
|
RU2758608C2
(ru)
|
2014-11-19 |
2021-11-01 |
Конинклейке Филипс Н.В. |
Способ диагностики с использованием hnl
|
|
EP3253799B1
(en)
*
|
2015-02-05 |
2020-12-02 |
Molecular Templates, Inc. |
Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
|
|
EP3262217A4
(en)
|
2015-02-24 |
2018-07-18 |
BioAtla LLC |
Conditionally active biological proteins
|
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
|
EP3770171A1
(en)
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
AU2016252771B2
(en)
|
2015-04-22 |
2021-12-16 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
US9687547B2
(en)
|
2015-05-28 |
2017-06-27 |
Immunomedics, Inc. |
T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
US10723793B2
(en)
|
2015-06-12 |
2020-07-28 |
Ludwig Institute For Cancer Research, Ltd. |
TGF-β3 specific antibodies and methods and uses thereof
|
|
CA2989269C
(en)
|
2015-06-15 |
2020-09-22 |
Robert Yongxin Zhao |
Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
|
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
IL296285A
(en)
|
2015-07-06 |
2022-11-01 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
CA2994841A1
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
TWI873952B
(zh)
|
2015-10-02 |
2025-02-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
WO2017078839A1
(en)
|
2015-11-02 |
2017-05-11 |
Bioatla, Llc |
Conditionally active polypeptides
|
|
EP3373937B1
(en)
|
2015-11-09 |
2021-12-22 |
R.P. Scherer Technologies, LLC |
Anti-cd22 antibody-maytansine conjugates and methods of use thereof
|
|
EP3389693A4
(en)
|
2015-12-18 |
2019-08-21 |
Agilvax, Inc. |
COMPOSITIONS AND METHODS RELATED TO XCT PEPTIDES
|
|
AU2016381992B2
(en)
|
2015-12-28 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
EP4711465A2
(en)
*
|
2016-04-14 |
2026-03-18 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
AU2017257254B2
(en)
|
2016-04-27 |
2022-02-24 |
Immunomedics, Inc. |
Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
|
CN109803680B
(zh)
|
2016-08-01 |
2024-05-17 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
|
AU2017335771A1
(en)
|
2016-09-28 |
2019-02-28 |
Musc Foundation For Research Development |
Antibodies that bind interleukin-2 and uses thereof
|
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
WO2018106895A1
(en)
|
2016-12-07 |
2018-06-14 |
Molecular Templates, Inc. |
Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
|
|
MX2019008840A
(es)
|
2017-01-25 |
2019-09-09 |
Molecular Templates Inc |
Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
|
|
EP3600283A4
(en)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
|
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
EP3630046B1
(en)
|
2017-05-30 |
2024-12-25 |
The Board of Regents of the University of Oklahoma |
Anti-doublecortin-like kinase 1 antibodies and methods of use
|
|
KR20200117992A
(ko)
*
|
2017-12-11 |
2020-10-14 |
트리페이스 리서치 앤드 디벨로프먼트 쓰리 코포레이션 |
항-cd22 항체-메이탄신 컨쥬게이트, 그것의 조합, 및 사용 방법
|
|
KR20250099256A
(ko)
|
2018-01-18 |
2025-07-01 |
프레드 허친슨 캔서 센터 |
세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
KR102871690B1
(ko)
|
2018-04-30 |
2025-10-16 |
리제너론 파마슈티칼스 인코포레이티드 |
Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
|
|
BR112020023145A2
(pt)
|
2018-05-17 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
|
|
WO2020053634A1
(en)
*
|
2018-09-16 |
2020-03-19 |
Habibi Anbouhi Mahdi |
Anti-cd22 heavy-chain variable domain antibody
|
|
EP3877053A1
(en)
|
2018-11-05 |
2021-09-15 |
Ludwig Institute for Cancer Research Ltd |
Humanized and variant tgf-beta3 specific antibodies and methods and uses thereof
|
|
CN113613725B
(zh)
|
2018-11-05 |
2025-09-23 |
路德维格癌症研究所有限公司 |
人源化和变体TGF-β1特异性抗体及其方法和用途
|
|
CN114096559B
(zh)
|
2019-03-27 |
2026-03-20 |
蒂嘉特克斯公司 |
工程化iga抗体及其使用方法
|
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
|
WO2022152282A1
(zh)
*
|
2021-01-18 |
2022-07-21 |
江苏先声药业有限公司 |
抗人cd22的单克隆抗体及其用途
|
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|
|
US12043671B2
(en)
|
2021-06-16 |
2024-07-23 |
Gundersen Lutheran Medical Foundation, Inc. |
Antibodies targeting an amphiregulin-derived cell surface neo-epitope
|
|
WO2023056240A2
(en)
|
2021-09-28 |
2023-04-06 |
Frontaim Biomedicines, Inc. |
Multiple formats of molecular complexes
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
KR20250073273A
(ko)
*
|
2022-09-23 |
2025-05-27 |
누클리디움 아게 |
고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
|
|
TW202426433A
(zh)
|
2022-09-23 |
2024-07-01 |
瑞士商紐利迪姆股份公司 |
成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
|
|
CN116333035B
(zh)
*
|
2022-12-07 |
2025-05-23 |
复旦大学附属肿瘤医院 |
靶向磷酸化akt蛋白的pet探针及其合成方法与应用
|
|
US20250109209A1
(en)
|
2023-10-03 |
2025-04-03 |
Absci Corporation |
Tl1a associated antibody compositions and methods of use
|
|
WO2025122885A1
(en)
|
2023-12-08 |
2025-06-12 |
Absci Corporation |
Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
|